Pentax will provide funding for research into biomarkers.

SRI International initiated a personalized medicine program to find cancer biomarkers to make diagnostic tools. This project is part of a multiyear collaboration with Pentax.


Pentax will provide research funding and R&D milestone payments to SRI as well as royalties on sales of any resulting products.


“Pentax and SRI are jointly addressing new opportunities in personalized medicine by developing diagnostic tools to assist in rapid and accurate selection of therapeutic options for treatment on an individual patient basis,” remarks Akira Yamamoto, research head at the Pentax Incubation Center and program director for the Pentax–SRI partnership.

Previous articleVirium Pharmaceuticals Gains Rights to Southern Research Institute’s Oncology Compound
Next articleSNPs Associated with Gene-Drug Interactions in Hypertension Identified